George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- January31 2004
- Volume 11
- Issue 2
Doctor Shortage Predicted
Author(s)Michael Sheehan
Advertisement
Mounting evidence from physicianrecruitment firms and experts in the fieldof physician workforce issues has led theCouncil of Graduate Medical Education(COGME; www.cogme.gov) to abandonits longstanding forecast of a doctor surplus.COGME now sees a doctor shortagein the offing, partly because of a trendamong younger physicians to work shorterhours. Also blended into the mix thatled to the reversal is an aging babyboomer population that will need morecare and a shift toward higher demandsfor specialist services as managed carebarriers crumble. COGME is adopting areport that calls for an additional 3000medical school graduates to counteractan estimated shortage of 85,000 medicaldoctors by 2020. The report also recommendsa change in the distribution of residencyopenings to more closely reflectmarket demand.
Articles in this issue
about 18 years ago
Understand the Fully Bundled Pensionsabout 18 years ago
Establish Year-Round Financial Planningabout 18 years ago
Understand the Expenses of Your Childabout 18 years ago
Learn the Secrets of Wilbur and Orvilleabout 18 years ago
Get the New Year Off to an Excellent Startabout 18 years ago
Don't Outlive Your Retirement Nest Eggabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Does Med School Affect Malpractice?about 18 years ago
With Asset Protection, Compliance Is Keyabout 18 years ago
Read a Pair of Classic Investment TomesAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
2
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5